Bristol Myers Squibb (CELG-RI) EBIT Margin Growth (3y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) EBIT Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBIT Margin Growth (3y) (Qtr) |
| 1 |
Gsk |
92,316,836.42 Bn |
92,316,831.46 Bn |
7.76 Bn |
10.00 |
| 2 |
Eli Lilly |
983.57 Bn |
978.29 Bn |
16.22 Bn |
2,500.00 |
| 3 |
Johnson & Johnson |
553.56 Bn |
531.50 Bn |
15.96 Bn |
-91.00 |
| 4 |
AbbVie |
383.35 Bn |
374.00 Bn |
10.78 Bn |
395.00 |
| 5 |
Merck |
281.71 Bn |
276.06 Bn |
12.09 Bn |
-4,555.00 |
| 6 |
Amgen |
182.20 Bn |
170.16 Bn |
5.87 Bn |
-53.00 |
| 7 |
Gilead Sciences |
153.71 Bn |
145.98 Bn |
5.52 Bn |
1,031.00 |
| 8 |
Pfizer |
143.75 Bn |
130.98 Bn |
-1.21 Bn |
-9,003.00 |
| 9 |
Bristol Myers Squibb |
109.71 Bn |
99.25 Bn |
8.07 Bn |
-338.00 |
| 10 |
Bristol Myers Squibb |
- |
- |
8.07 Bn |
-338.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
-338.00 |
| Dec 31, 2025 |
-1,458.00 |
| Sep 30, 2025 |
-134.00 |
| Jun 30, 2025 |
-662.00 |
| Mar 31, 2025 |
618.00 |
| Dec 31, 2024 |
-3,342.00 |
| Sep 30, 2024 |
-962.00 |
| Jun 30, 2024 |
-855.00 |
| Mar 31, 2024 |
-11,896.00 |
| Dec 31, 2023 |
11,139.00 |
| Sep 30, 2023 |
-104.00 |
| Jun 30, 2023 |
152.00 |
| Mar 31, 2023 |
3,859.00 |
| Dec 31, 2022 |
2,655.00 |
| Sep 30, 2022 |
606.00 |
| Jun 30, 2022 |
-329.00 |
| Mar 31, 2022 |
-935.00 |
| Dec 31, 2021 |
-240.00 |
| Sep 30, 2021 |
-1,027.00 |
| Jun 30, 2021 |
1,174.00 |
